Alimera Receives Marketing Authorization In Spain for ILUVIEN

Alimera Sciences, Inc.,

(Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced the Spanish Agency of Drugs and Medical Devices (Agencia Espanola de Medicamentos y Productos Sanitarios) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. This marketing authorization follows the completion of the Decentralized Regulatory Procedure (DCP) in the European Union (EU), in which the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, serving as the Reference Member State (RMS), delivered a positive outcome for ILUVIEN along with six Concerned Members States (CMS), specifically Austria, France, Germany, Italy, Portugal and Spain. The Spanish authorization is the sixth national approval in the EU, preceded by Austria, the United Kingdom, Portugal, France and Germany. "ILUVIEN has now been granted marketing authorizations in six of the seven EU countries in which we have applied," said Dan Myers, president and chief executive officer, Alimera. "With our European management team now on board, we are looking forward to the initial commercial launch of ILUVIEN in Germany, expected during the first quarter of 2013. In